Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations-Reference-Cited by-同舟云学术

Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations

Published:2017-02-20 Issue:6 Volume:35 Page:689-690
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Wang-Gillam Andrea¹,Von Hoff Daniel¹,Siveke Jens¹,Hubner Richard¹,Belanger Bruce¹,Pipas J. Marc¹,Chen Li-Tzong¹

Affiliation:

1. Andrea Wang-Gillam, Washington University School of Medicine, St. Louis, MO; Daniel Von Hoff, TGen, Phoenix; and HonorHealth, Scottsdale, AZ; Jens Siveke, Klinikum rechts der Isar der T U München, Germany; Richard Hubner, The Christie NHS Foundation Trust, Manchester, United Kingdom; Bruce Belanger and J. Marc Pipas, Merrimack Pharmaceuticals, Cambridge, MA; and Li-Tzong Chen, National Health Research Institutes, Tainan, Taiwan

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.70.1607

Reference3 articles.

1. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

2. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

3. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study;BMC Cancer;2023-04-11

2. Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study;2022-12-01

3. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients;OncoImmunology;2020-01-01

4. Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks;Journal of Clinical Medicine;2019-05-17

5. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer;Journal of Pharmacology and Experimental Therapeutics;2019-02-22